14 January 2020 - Myeloma New Zealand is today calling on PHARMAC to make good on their proposal to widen access to blood cancer treatment lenalidomide (Revlimid) from April this year, allowing eligible patients access the subsidised drug earlier in their course of treatment.

As one of several groups that marched on Parliament in 2019 presenting petitions demanding an overhaul of New Zealand’s drug funding process and budget, Myeloma New Zealand are advocating for improved treatment access for the country’s second most common blood cancer.

Dr Ken Romeril – consultant haematologist and founder of Myeloma New Zealand says “You often see a better response to novel treatments like lenalidomide when used up front, so we are calling on PHARMAC to make good on their proposal and allow myeloma patients to access subsidised lenalidomide earlier in their treatment.

Read Myeloma NZ press release